Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.58% | -81.77% | -89.64% | 33.07% | 190.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.58% | -81.77% | -89.64% | 33.07% | 190.15% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -78.58% | -81.77% | -89.64% | 33.07% | 190.15% |
| SG&A Expenses | 46.00% | 25.27% | 47.89% | 30.09% | 46.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.05% | 26.85% | 45.93% | 83.46% | 147.83% |
| Operating Income | -117.89% | -34.74% | -57.30% | -85.93% | -146.34% |
| Income Before Tax | -126.55% | -46.04% | -79.64% | -114.66% | -169.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -126.55% | -46.04% | -79.64% | -114.66% | -169.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.55% | -46.04% | -79.64% | -114.66% | -169.24% |
| EBIT | -117.89% | -34.74% | -57.30% | -85.93% | -146.34% |
| EBITDA | -117.98% | -34.76% | -57.33% | -86.01% | -146.52% |
| EPS Basic | -76.48% | -32.30% | -71.64% | -53.91% | -13.87% |
| Normalized Basic EPS | -64.60% | -27.98% | -73.63% | -57.86% | -24.22% |
| EPS Diluted | -76.48% | -32.30% | -71.64% | -53.91% | -13.87% |
| Normalized Diluted EPS | -64.60% | -27.98% | -73.63% | -57.86% | -24.22% |
| Average Basic Shares Outstanding | 28.37% | 10.39% | 4.66% | 39.45% | 136.43% |
| Average Diluted Shares Outstanding | 28.37% | 10.39% | 4.66% | 39.45% | 136.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |